CNTX
Context Therapeutics Inc
NASDAQ: CNTX · HEALTHCARE · BIOTECHNOLOGY
$0.61
-1.57% today
Updated 2026-07-30
Market cap
$54.42M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.41
Dividend yield
—
52W range
$1 – $4
Volume
2.8M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$5.38
+785.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z 1.17 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-11.47M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.84M | $-23.96M | $-26.73M | $-36.12M | $-8.68M |
| EPS | — | — | — | — | $-0.41 |
| Free cash flow | $-14.09M | $-21.05M | $-29.31M | $-26.42M | $-11.47M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Context Therapeutics Inc trades at $0.61. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 1.17, it sits in the distress.
Frequently asked questions
What is Context Therapeutics Inc's stock price?
Context Therapeutics Inc (CNTX) trades at $0.61.
Is Context Therapeutics Inc overvalued?
Context Therapeutics Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Context Therapeutics Inc (CNTX)?
The 12-month analyst consensus target is $5.38, about 785.9% above the current $0.61. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Context Therapeutics Inc's Altman Z-Score is 1.17, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-77.06%
Beta1.75
50D MA$1.35
200D MA$1.75
Shares out0.09B
Float0.04B
Short ratio—
Avg volume2.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—